Kazuhiko Yonekura

Tsukuba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.

Journal: Cancer research

Published: October 29, 2019

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

Journal: Molecular cancer therapeutics

Published: December 04, 2017

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

Journal: The Journal of biological chemistry

Published: March 31, 2016

High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.

High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.

Journal: PloS one

Published: January 17, 2016

TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.

TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.

Journal: Molecular cancer therapeutics

Published: November 23, 2014

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 16, 2014

The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.

The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.

Journal: Molecular cancer therapeutics

Published: October 22, 2013

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

Journal: Cancer science

Published: August 28, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026